Table 4.
A. Relative risk* of Glaucoma by Implant vs. Systemic Treatment (Tx) adjusted for Alternative Time-Updated¶ Definitions of Intraocular Pressure (IOP) Categorization, eyes with uveitis treated with [fluocinolone acetonide) Implant or Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study
B. Relative risk* of Glaucoma by Alternative Intraocular Pressure Categorizations in the Implant and Systemic Treatment Groups and Both Combined; eyes with uveitis treated with [fluocinolone acetonide) Implant or Systemic Therapy in the MUST Trial and Follow-up Study
| Model | Relative Risk Treatment (Implant vs Systemic) | 95% CI | P-value | Generalized R-squared† | AIC‡ |
|---|---|---|---|---|---|
| Tx | 5.9 | 3.2, 10.8 | <0.001 | 0.34 | 1024.2 |
| Tx + Baseline IOP | 5.8 | 3.2, 10.6 | <0.001 | 0.37 | 1020.5 |
| Tx + Time-updated IOP | 5.1 | 2.7, 9.5 | <0.001 | 0.44 | 1006.6 |
| Tx + Time-updated Average IOP | 3.6 | 1.9, 6.9 | <0.001 | 0.53 | 984.1 |
| Tx + Time-updated Max IOP | 3.1 | 1.6, 6.0 | 0.001 | 0.54 | 983.8 |
| Adjusted for time-dependent intra-ocular injections∥ | |||||
| Tx | 5.7 | 3.1, 10.3 | <0.001 | 0.35 | 1024.3 |
| Tx + Baseline IOP | 5.6 | 3.1, 10.2 | <0.001 | 0.38 | 1020.5 |
| Tx + Time-updated IOP | 4.9 | 2.6, 9.1 | <0.001 | 0.44 | 1007.1 |
| Tx + Time-updated Average IOP | 3.5 | 1.9, 6.7 | <0.001 | 0.54 | 984.9 |
| Tx + Time-updated Max IOP | 2.9 | 1.5, 5.7 | 0.001 | 0.54 | 983.9 |
| Relative Risk IOP (per mmHg) | |||||
| Both Groups | |||||
| Baseline IOP | 1.07 | 1.01, 1.13 | 0.02 | 0.04 | 1074.3 |
| Time-updated IOP | 1.07 | 1.05, 1.09 | <0.001 | 0.20 | 1048.1 |
| Time-updated Average IOP | 1.23 | 1.18, 1.28 | <0.001 | 0.43 | 1006.8 |
| Time-updated Max IOP | 1.09 | 1.07, 1.11 | <0.001 | 0.46 | 998.8 |
| Systemic Group | |||||
| Baseline IOP | 1.11 | 1.01, 1.21 | 0.03 | 0.09 | 147.2 |
| Time-updated IOP | 1.22 | 1.14, 1.30 | <0.001 | 0.63 | 129.3 |
| Time-updated Average IOP | 1.27 | 1.12, 1.44 | <0.001 | 0.40 | 138.2 |
| Time-updated Max IOP | 1.12 | 1.06, 1.18 | <0.001 | 0.45 | 136.8 |
| Implant Group | |||||
| Baseline IOP | 1.07 | 1.00, 1.14 | 0.04 | 0.04 | 811.8 |
| Time-updated IOP | 1.05 | 1.03, 1.07 | <0.001 | 0.10 | 803.9 |
| Time-updated Average IOP | 1.18 | 1.13, 1.23 | <0.001 | 0.28 | 778.6 |
| Time-updated Max IOP | 1.07 | 1.05, 1.09 | <0.001 | 0.29 | 776.4 |
Derived from Cox regression accounting for between-eye correlation; 6,832 complete case observations
Propor:on of explained variance for proportional hazards models.20
Akaike Information Criterion (best model is one with lowest AIC)21
IOP was defined 4 ways: 1) Baseline IOP using the IOP at the baseline visit; 2) time-updated IOP using the IOP at that visit; 3) time-updated average IOP using the average IOP up through that visit; and 4) time-updated max IOP using the highest IOP up through that visit.
Relative risk (95% CI) for glaucoma in patients receiving vs not receiving intra-ocular injections was 0.56 (0.23, 1.33); p=0.19 in model including Tx; 0.55 (0.23, 1.30); p=0.17 in model including Tx + Baseline IOP; 0.60 (0.25, 1.43); p=0.25 in model including Tx + time-updated IOP; 0.62 (0.25, 1.47); p=0.28 in model including Tx + time-updated average IOP; and 0.55 (0.23, 1.32); p=0.18 in model including Tx + time-updated max IOP.